A non-canonical role for E2F1 in driving the development of neuroendocrine prostate cancer
Development of neuroendocrine prostate cancer (NEPC) is increasing in the face of AR-targeted therapies. Dunmore et al. demonstrate that E2F1 is associated with inducing NEPC gene expression and, through direct genome-wide mapping, have highlighted key E2F1 targets.